托特罗定与毛果芸香碱联合治疗膀胱过度活动症患者的疗效与安全性
这项多中心、随机、双盲、平行、阳性对照研究纳入膀胱过度活动症患者,比较2 mg托特罗定联合9 mg毛果芸香碱与托特罗定单药治疗12周的疗效与安全性。联合组每日排尿次数变化非劣于单药组,且12周口干发生率更低(30.0% vs 42.9%,p=0.009),口干问卷总分及视觉模拟量表改善更明显。
要点
- 联合组每日排尿次数变化-1.49 vs 单药组-1.74,平均差异-0.26(95%CI -0.79-0.27),证实非劣效。
- 12周口干发生率联合组30.0% vs 单药组42.9%(p=0.009),联合组更低。
- 两组膀胱过度活动症相关次要疗效指标均改善,12周时组间无显著差异。
核心结论
- 托特罗定联合毛果芸香碱可减轻膀胱过度活动症患者的口干,同时保持与托特罗定相似的抗胆碱能疗效。
研究设计与样本
- 多中心、随机、双盲、平行、阳性对照研究,纳入膀胱过度活动症患者,随机接受联合治疗或2 mg托特罗定每日两次,双盲期12周,之后所有患者接受联合治疗12周。
主要发现
- 每日排尿次数从基线至12周的平均变化联合组为-1.49,托特罗定单药组为-1.74,平均差异-0.26(95%CI -0.79-0.27),证实非劣效。
- 12周口干发生率联合组为30.0%,托特罗定单药组为42.9%(p=0.009),联合组更低。
- 12周时两组膀胱过度活动症相关次要疗效指标均改善,组间无显著差异。
- 口干问卷总分及口干视觉模拟量表从基线的变化联合组显著低于托特罗定单药组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the efficacy and safety of a combination of 2 mg tolterodine and 9 mg pilocarpine, vs tolterodine monotherapy in patients with overactive bladder. MATERIALS AND METHODS: We enrolled patients with overactive bladder symptoms in a multicenter, randomized, double-blind, parallel, active control study. Patients were randomized to the combination or 2 mg tolterodine twice daily for 12 weeks. After the double-blind period finished all patients were started on the combination for 12 weeks. Study co-primary end points were the change from baseline in the mean number of daily micturitions and cumulative incidence of dry mouth at the end of 12 weeks. Secondary end points were other overactive bladder symptoms, the total xerostomia inventory score and results of a visual analogue scale for dry mouth at the end of 12 and 24 weeks. RESULTS: The mean change in the number of daily micturitions from baseline to 12 weeks was -1.49 and -1.74 in the combination and tolterodine monotherapy groups, respectively. The mean difference was -0.26 (95% CI -0.79-0.27), confirming noninferiority. At 12 weeks the incidence of dry mouth was lower in the combination group than in the tolterodine monotherapy group (30.0% vs 42.9%, p = 0.009). All secondary and other efficacy outcomes related to overactive bladder symptoms improved in each group with no significant differences between the groups at 12 weeks. Changes from baseline in the total xerostomia inventory score and the visual analogue scale for dry mouth were significantly lower in the combination group than in the tolterodine monotherapy group. CONCLUSIONS: Tolterodine and pilocarpine alleviated dry mouth in patients with overactive bladder while maintaining anticholinergic efficacy similar to that of tolterodine.
引用
- Ko KJ, Kim KH, Kim SW, et al. Efficacy and Safety of Tolterodine and Pilocarpine in Patients with Overactive Bladder. J Urol. 2019. PMID: 31009289. doi:10.1097/JU.0000000000000281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。